-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Watson Pharmaceuticals stated in an announcement on institutional research that the overall market size of Changsong (polyethylene glycol 4000) powder is not large
.
The centralized procurement was selected by several companies.
Since the company already had the largest market share of this category in China before the centralized procurement, many winning bids to segment the market have a greater impact on the company’s revenue scale in this category
.
Constipation is a common disease that seriously affects people's quality of life.
Drug therapy is the main treatment method at present.
The 2013 "Chinese Guidelines for Diagnosis and Treatment of Chronic Constipation" pointed out that "polyethylene glycol improves the frequency of weekly defecation, fecal properties and The efficacy of constipation-related symptoms and other aspects is significantly better than that of other treatment groups, and it has been recommended by many international guidelines and consensus opinions for the long-term treatment of patients with chronic constipation
.
”
Polyethylene glycol 4000 powder is mainly used for the symptomatic treatment of constipation in adults and children over 8 years old (including 8 years old)
.
According to the catalogue of generic drug reference preparations (the first batch) published by the State Food and Drug Administration, the drug was developed by Ipsen Pharma (trade name: Fusong, 10g, powder), registered in France in 1995, and started clinical treatment in 1996 Adult constipation, registered and sold in China in 1999, the company expanded its indication to treat constipation in children over 8 years old in 2003
.
In addition, the drug has been included in the "National Essential Drug List" and "National Medical Insurance List"
.
According to data from Minet.
com, the terminal sales of polyethylene glycol 4000 powder in China's public medical institutions in 2017 were 136 million yuan.
In 2018, the drug was sold in China's urban public hospitals, county-level public hospitals and urban retail pharmacies.
The total amount is 169 million yuan
.
In recent years, the polyethylene glycol 4000 bulk market has shown a growth trend
.
The industry predicts that by 2022, the market size of polyethylene glycol hospitals in China is expected to reach 300 million yuan
.
Polyethylene glycol 4000 powder is one of the key products of Watson Pharmaceuticals.
From 2016 to 2018, the sales revenue of this product showed an increasing trend, with sales reaching 21.
2614 million yuan, 27.
0307 million yuan and 35.
3824 million yuan respectively.
The compound growth rate is 29.
00%
.
According to the statistics of Minet, in 2018, Changsong (polyethylene glycol 4000 powder) accounted for 22.
45% of the market share of domestic urban public hospitals, ranking first among domestic brands
.
At present, the domestic manufacturers of the drug also include Chongqing Sino Biopharmaceutical Co.
, Ltd.
, Hunan Huana Pharmaceutical Co.
, Ltd.
, Chongqing Sino Biopharmaceutical Co.
, Ltd.
Pharmaceutical consistency evaluation
.
On December 28, 2018, Watson Pharmaceuticals announced that the company's polyethylene glycol 4000 powder (specification: 10g) passed the consistency evaluation
.
Watson Pharmaceuticals has become the first company in this category to be reviewed
.
Subsequently, Sino Bio's polyethylene glycol 4000 powder announced the completion of the consistency evaluation study, which was the second to obtain the consistency evaluation approval for this variety
.
On June 14, 2019, the polyethylene glycol 4000 powder of Hunan Huana Pharmaceutical Factory has also passed the consistency evaluation
.
On September 29, 2019, Ma Yinglong issued an announcement saying that the company received the "Drug Supplementary Application Approval" issued by the State Food and Drug Administration for polyethylene glycol 4000 powder, which passed the consistency evaluation of the quality and efficacy of generic drugs
.
In the second batch of national centralized drug procurement, polyethylene glycol 4000 powder (10g) was won by 4 companies including Watson Pharmaceuticals
.
After winning the bid, Watson Pharma once stated in the announcement that it will help the company to further enhance the market coverage of its products, expand sales, and enhance the company's brand influence
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The centralized procurement was selected by several companies.
Since the company already had the largest market share of this category in China before the centralized procurement, many winning bids to segment the market have a greater impact on the company’s revenue scale in this category
.
Constipation is a common disease that seriously affects people's quality of life.
Drug therapy is the main treatment method at present.
The 2013 "Chinese Guidelines for Diagnosis and Treatment of Chronic Constipation" pointed out that "polyethylene glycol improves the frequency of weekly defecation, fecal properties and The efficacy of constipation-related symptoms and other aspects is significantly better than that of other treatment groups, and it has been recommended by many international guidelines and consensus opinions for the long-term treatment of patients with chronic constipation
.
”
Polyethylene glycol 4000 powder is mainly used for the symptomatic treatment of constipation in adults and children over 8 years old (including 8 years old)
.
According to the catalogue of generic drug reference preparations (the first batch) published by the State Food and Drug Administration, the drug was developed by Ipsen Pharma (trade name: Fusong, 10g, powder), registered in France in 1995, and started clinical treatment in 1996 Adult constipation, registered and sold in China in 1999, the company expanded its indication to treat constipation in children over 8 years old in 2003
.
In addition, the drug has been included in the "National Essential Drug List" and "National Medical Insurance List"
.
According to data from Minet.
com, the terminal sales of polyethylene glycol 4000 powder in China's public medical institutions in 2017 were 136 million yuan.
In 2018, the drug was sold in China's urban public hospitals, county-level public hospitals and urban retail pharmacies.
The total amount is 169 million yuan
.
In recent years, the polyethylene glycol 4000 bulk market has shown a growth trend
.
The industry predicts that by 2022, the market size of polyethylene glycol hospitals in China is expected to reach 300 million yuan
.
Polyethylene glycol 4000 powder is one of the key products of Watson Pharmaceuticals.
From 2016 to 2018, the sales revenue of this product showed an increasing trend, with sales reaching 21.
2614 million yuan, 27.
0307 million yuan and 35.
3824 million yuan respectively.
The compound growth rate is 29.
00%
.
According to the statistics of Minet, in 2018, Changsong (polyethylene glycol 4000 powder) accounted for 22.
45% of the market share of domestic urban public hospitals, ranking first among domestic brands
.
At present, the domestic manufacturers of the drug also include Chongqing Sino Biopharmaceutical Co.
, Ltd.
, Hunan Huana Pharmaceutical Co.
, Ltd.
, Chongqing Sino Biopharmaceutical Co.
, Ltd.
Pharmaceutical consistency evaluation
.
On December 28, 2018, Watson Pharmaceuticals announced that the company's polyethylene glycol 4000 powder (specification: 10g) passed the consistency evaluation
.
Watson Pharmaceuticals has become the first company in this category to be reviewed
.
Subsequently, Sino Bio's polyethylene glycol 4000 powder announced the completion of the consistency evaluation study, which was the second to obtain the consistency evaluation approval for this variety
.
On June 14, 2019, the polyethylene glycol 4000 powder of Hunan Huana Pharmaceutical Factory has also passed the consistency evaluation
.
On September 29, 2019, Ma Yinglong issued an announcement saying that the company received the "Drug Supplementary Application Approval" issued by the State Food and Drug Administration for polyethylene glycol 4000 powder, which passed the consistency evaluation of the quality and efficacy of generic drugs
.
In the second batch of national centralized drug procurement, polyethylene glycol 4000 powder (10g) was won by 4 companies including Watson Pharmaceuticals
.
After winning the bid, Watson Pharma once stated in the announcement that it will help the company to further enhance the market coverage of its products, expand sales, and enhance the company's brand influence
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
